Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$47.82 USD
-0.69 (-1.42%)
Updated Oct 2, 2024 10:04 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Avidity Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -212.22 | -174.00 | -118.01 | -44.36 | -24.73 |
Depreciation/Amortization & Depletion | -9.17 | 0.77 | 0.82 | 0.41 | 0.42 |
Net Change from Assets/Liabilities | 61.13 | 9.82 | 5.34 | 2.33 | 19.36 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 41.20 | 27.14 | 17.04 | 4.50 | 7.45 |
Net Cash From Operating Activities | -119.06 | -136.27 | -94.81 | -37.12 | 2.49 |
Property & Equipment | -4.23 | -2.82 | -3.74 | -1.09 | -0.24 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -125.84 | -187.13 | -78.78 | -6.69 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -130.07 | -189.96 | -82.52 | -7.79 | -0.24 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 93.86 | 346.17 | 187.58 | 300.75 | 72.69 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -4.68 | 16.65 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -11.26 | -24.03 | -0.11 |
Net Cash from Financing Activities | 93.86 | 346.17 | 176.32 | 272.04 | 89.23 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -155.27 | 19.95 | -1.01 | 227.14 | 91.49 |
Cash at Beginning of Period | 340.65 | 320.70 | 321.71 | 94.58 | 3.09 |
Cash at End of Period | 185.38 | 340.65 | 320.70 | 321.71 | 94.58 |
Diluted Net EPS | -2.91 | -3.34 | -2.85 | -2.05 | NA |
Fiscal Year End for Avidity Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -139.65 | -68.86 | -212.22 | -151.78 | -99.42 |
Depreciation/Amortization & Depletion | -6.11 | -2.32 | -9.17 | -6.55 | -4.15 |
Net Change from Assets/Liabilities | -14.40 | -10.34 | 61.13 | -7.77 | -15.18 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 24.77 | 11.13 | 41.20 | 30.53 | 19.98 |
Net Cash From Operating Activities | -135.38 | -70.38 | -119.06 | -135.57 | -98.77 |
Property & Equipment | -1.45 | -0.92 | -4.23 | -3.37 | -2.44 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -306.17 | -31.83 | -125.84 | -177.75 | -147.19 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -307.62 | -32.75 | -130.07 | -181.11 | -149.63 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 456.39 | 389.45 | 93.86 | 61.97 | 61.93 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 379.78 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 836.17 | 389.45 | 93.86 | 61.97 | 61.93 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 393.17 | 286.32 | -155.27 | -254.70 | -186.47 |
Cash at Beginning of Period | 185.38 | 185.38 | 340.65 | 340.65 | 340.65 |
Cash at End of Period | 578.55 | 471.70 | 185.38 | 85.95 | 154.18 |
Diluted Net EPS | -0.65 | -0.79 | -0.80 | -0.71 | -0.66 |